Multiple Myeloma Clinical Trials in Dallas, Texas

12 studies are recruiting for multiple myeloma in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

   Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas - Southwestern Medical Center /ID# 271914, Dallas, Texas

   Locations

   51 in total

   Run by

   AbbVie

   See if you can join NCT06953960 on ClinicalTrials.gov

2. A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

   A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas

   Locations

   29 in total

   Run by

   K36 Therapeutics, Inc.

   See if you can join NCT05651932 on ClinicalTrials.gov

3. A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

   Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapse…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas - Southwestern Medical Center /ID# 274360, Dallas, Texas

   Locations

   36 in total

   Run by

   AbbVie

   See if you can join NCT06892522 on ClinicalTrials.gov

4. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UT Southwestern Medical Center, Dallas, Texas

   Locations

   52 in total

   Run by

   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

   See if you can join NCT06297226 on ClinicalTrials.gov

5. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

   The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Locations

   270 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05552222 on ClinicalTrials.gov

6. A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

   This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Dallas, Texas

   Locations

   13 in total

   Run by

   AstraZeneca

   See if you can join NCT07073547 on ClinicalTrials.gov

7. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Baylor University Medical Center, Dallas, Texas

   Locations

   150 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07258511 on ClinicalTrials.gov

8. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Baylor University Medical Center, Dallas, Texas

   Locations

   173 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07518186 on ClinicalTrials.gov

9. MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

   The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments befo…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas, Texas

   Locations

   270 in total

   Run by

   Pfizer

   See if you can join NCT06152575 on ClinicalTrials.gov

10. A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Texas Oncology - Dallas - Worth Street /ID# 280064, Dallas, Texas

    Locations

    46 in total

    Run by

    AbbVie

    See if you can join NCT05650632 on ClinicalTrials.gov

11. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that r…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas Southwestern, Dallas, Texas

    Locations

    42 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT05137054 on ClinicalTrials.gov

12. Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

    The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.

    Stage

    Not phased

    Ages

    Any age

    Site

    Ut Southwestern, Dallas, Texas

    Locations

    8 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT06357754 on ClinicalTrials.gov